Summary & Overview
CPT 81528: Stool DNA and Fecal Hemoglobin Colorectal Cancer Screening Test
CPT code 81528 represents a stool-based colorectal cancer screening assay that combines fecal hemoglobin testing with real-time amplification of multiple DNA markers and an algorithmic interpretation to report a positive or negative result. This molecular and immunochemical diagnostic service matters nationally because it supports noninvasive screening, can increase screening uptake, and has implications for early detection pathways and downstream diagnostic workflows.
Key payers examined in coverage and reimbursement discussions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The analysis addresses how major payers classify and reimburse advanced stool-based tests, where coverage policies and prior authorization requirements may affect access, and how Medicare policy frameworks influence national uptake.
Readers will find benchmarks on coding and payer coverage, a concise clinical context for interpreting the test's role in screening strategies, and summaries of policy considerations that affect utilization and billing. The report highlights typical use cases, site-of-service implications for clinical laboratories and reference labs, and areas where payers' policy language may differ. Data not available in the input is noted where specific payer policy details or utilization metrics are absent.
Billing Code Overview
CPT code 81528 describes a laboratory service that analyzes a stool sample for colorectal cancer screening. The test includes technical laboratory assays for fecal hemoglobin and real-time amplification of 10 DNA markers, followed by an algorithmic analysis combining patient data and laboratory results to report a positive or negative screening outcome.
-
Service type: Laboratory molecular and immunochemical diagnostic testing with algorithmic interpretation
-
Typical site of service: Clinical laboratory or reference laboratory performing stool-based colorectal cancer screening tests
Clinical & Coding Specifications
Clinical Context
A 58-year-old average-risk adult receives a commercially available stool-based colorectal cancer screening kit by mail. The patient collects a single stool specimen at home and returns it to a central laboratory. The laboratory performs a fecal hemoglobin immunoassay and real-time molecular amplification targeting a panel of 10 DNA markers associated with colorectal neoplasia. A laboratory technologist runs the analytic instruments, processes controls, and then executes a validated algorithm that integrates the molecular results, fecal hemoglobin level, and limited patient data (age, sex, prior screening history) to generate a single binary report: positive (requires diagnostic colonoscopy) or negative (routine screening interval). Typical workflow steps: kit accessioning, specimen integrity check, fecal hemoglobin assay, nucleic acid extraction and amplification, quality control review, algorithmic result generation, and final result reporting to the ordering clinician or screening program. Typical site of service is an independent clinical laboratory or hospital-based laboratory performing high-complexity molecular diagnostics. Typical patient scenario: screening of adults aged 45–75 for colorectal cancer who prefer non-invasive home testing or who missed colonoscopy; results guide need for diagnostic colonoscopy or routine surveillance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional component (interpretation or physician component) if separate from the laboratory technical work. |